Feb 6, 2026
Trump ex program and Zepbound
initiative secured agreements with and to sharply reduce cash and government prices for drugs, including Lilly’s tirzepatide (Zepbound), while expanding limited and access under new terms; the changes...
Medicare Coverage
Medicare's coverage of sacral neuromodulation procedures.
Fact-Checks
2 resultsJan 7, 2026
Which regulatory approvals and payer coverage decisions have most affected patient access to sacral neuromodulation in the last five years?
Over the past five years, two interlocking forces have driven patient access to sacral neuromodulation (SNM): a flurry of FDA device approvals that expanded the available implants and indications, and...